Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 to 90 years.~* Both genders.~* Clinical diagnosis of grade I to III pterygium (temporal, nasal, or bitemporal).~* Possibility of going to the revisions when indicated.~Exclusion Criteria:~* Subjects with topical or systemic medication that interfere decisively in the results of the study; such as topical immunomodulators, NSAIDs, antihistamines, corticosteroids, artificial tears with conservative, vasoconstrictors etc.~* Subjects (female) with active sexual life who do not use a contraceptive method.~* Subjects of the female sex in a pregnant state or who are breastfeeding.~* Subjects of the female sex with pregnancy test in positive urine.~* Positive substance abuse~* Subjects who have participated in any clinical research study in the last 40 days.~* Subjects legally or mentally incapacitated to give their informed consent for their participation in this study.~* Subjects that can not comply with the appointments or with all the requirements of the Protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- PRO-155 (Type: EXPERIMENTAL): Pro-155: 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac for 20 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac

Based on this trial design, predict the completion outcome and termination type (if applicable).